Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2596 to 2610 of 9044 results

  1. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Kodex EPD system MT575 (MIB260)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Dupilumab for treating chronic spontaneous urticaria inadequately controlled by H1 antihistamines in children 2 to 11 years [TSID12421]

    Awaiting development Reference number: GID-TA12472 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Ruxuplam for treating Huntington's disease [TSID12429]

    Awaiting development Reference number: GID-TA12476 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date:  10 March 2027

    Technology appraisal guidance
    In development

  9. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Epilepsies in children, young people and adults (SeLECTS)

    In development Reference number: GID-NG10453 Expected publication date:  05 August 2026

    NICE guideline
    In development

  11. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development

  12. Pulsed Field Ablation for Atrial Fibrillation

    Awaiting development Reference number: GID-HTG10866 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  14. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  15. CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)

    In development Reference number: GID-HTE10085 Expected publication date:  02 December 2026

    In development